Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026GlobeNewsWire · 3 days ago
American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk StratificationGlobeNewsWire · 6 days ago
Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging BiomarkersGlobeNewsWire · 6 days ago
Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026GlobeNewsWire · Oct 13, 2026
Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive TestsZacks Investment Research · Sep 28, 2026
Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) MonitoringGlobeNewsWire · Sep 24, 2026Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate the risk of lung cancer in patients with suspicious nodules, aiding in the reclassification of malignancy risk and guiding appropriate treatment pathways.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$0.90 | -$0.71 | Beat |
| May 4, 2026 | -$1.26 | -$0.81 | Beat |
| Feb 26, 2026 | -$1.05 | -$0.49 | Beat |
| Nov 3, 2025 | -$1.60 | -$1.16 | Beat |
| Aug 7, 2025 | -$1.40 | -$1.60 | Miss |
| May 13, 2025 | -$1.40 | -$1.60 | Miss |